HGC019
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | mRNA |
| Clinical data | |
| Other names | HGCO19, Gemcovac, GEMCOVAC-19 |
| Routes of administration | Intramuscular |
| ATC code |
|
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
.svg.png){kind=small} COVID-19 portal |
HGC019 is a mRNA and Self-amplifying mRNA (saRNA) based COVID-19 vaccine candidate being developed by Gennova Biopharmaceuticals and HDT Bio Corp. with active support from NIH under The Indo-US Vaccine Action Program (VAP) and Department of Biotechnology, India.[1]
Clinical trials
The phase-I trials began in February 2021 after receiving permission from Drugs Controller General of India (DGCI),[2][3] to evaluate the safety and immunogenicity of the vaccine candidate in about 120 participants consisting of age group (18–70) years.[4]
The phase-II trials is planned to conduct with 500 participants from the age group (18–75) years.[4] On 24 August 2021, the Drugs Controller General of India gave a go for phase II/III trials after it was found to be safe, tolerable, and immunogenic in the phase I trial results.[5][6][7]
Economics
The company has received a funding of ₹250 crore (around US$33.5 million) from Government of India based on the clinical trials progress.[8]
References
- ^ "mRNA Vaccines – HGC019". Gennova Biopharmaceuticals Limited. Archived from the original on 3 May 2021. Retrieved 13 January 2021.
- ^ "Indigenous mRNA vaccine candidate supported by DBT gets Drug Controller nod to initiate Human clinical trials" (Press release). Press Information Bureau. Retrieved 13 January 2021.
- ^ Raghavan P (15 December 2020). "Pune-based Gennova to begin human trials of its Covid vaccine 'soon'". The Indian Express.
- ^ a b "Safety and immunogenicity study of mRNA based vaccine (HGCO19) against COVID-19 in healthy adult participants". ctri.nic.in. Clinical Trials Registry India. Retrieved 5 June 2021.
- ^ "DBT-BIRAC supported Nation's first mRNA-based vaccine found to be safe gets a nod from the Drugs Controller General of India DCG(I) to move into Phase II/III trial" (Press release). Press Information Bureau. Retrieved 25 August 2021.
- ^ "India's first mRNA vaccine found to be safe, given nod for Phase II/III trial". mint. 24 August 2021.
- ^ Singh S (24 August 2021). "India approves further trials for first homegrown mRNA COVID-19 shot". Reuters.
- ^ Geeta N (26 May 2021). "Trials of India's first mRNA Covid vaccine by Gennova on track". The Financial Express.
External links
- "India's mRNA vaccine candidate advances to human trial phase". Hindustan Times.